Vigil Neuroscience rises as FDA lifts partial hold on brain disease therapy

Vigil Neuroscience

30/03/2023 15:25

** Shares of drug developer Vigil Neuroscience  VIGL.O  rise
~1.4% to $10.54
    ** Co says the U.S. Food and Drug Administration (FDA) has
lifted its partial clinical hold on its experimental therapy to
treat a type of neurological disease which affects the brain
    ** FDA has lifted the partial hold on co's lead therapy
candidate, VGL101, based on supporting clinical data from an
ongoing early-stage trial -VIGL  
    ** VGL101 is being tested to treat adult-onset
leukoencephalopathy with axonal spheroids and pigmented glia
(ALSP)-VIGL  
    ** ALSP is a neurological condition caused by changes to
certain areas of the brain which usually begin in a person's
forties and worsen over time
    ** FDA had placed a partial clinical hold on doses greater
than 20 mg/kg for VGL101 -VIGL
    ** Co expects to report the full data from the early-stage
trial testing up to 60 mg/kg dosage in H2 this year 
    ** Stock lost ~17.8% since IPO in Jan 2022

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))